Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer entities : Natera, inc. save search
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 2.12%
H: 4.35%
C: 2.25%
bladder positive cancer trial
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: -0.6%
H: 2.8%
C: 2.25%
cancer trials trial
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Published: 2024-03-18 (Crawled : 12:30) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 0.19%
H: 1.46%
C: 0.48%
cancer trial
New Study Validates Signatera™ in Endometrial Cancer
Published: 2024-02-05 (Crawled : 13:30) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: -0.89%
H: 2.74%
C: 2.52%
cancer study
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: -1.07%
H: 1.73%
C: 0.46%
lung cancer publication risk
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 1.08%
H: 0.45%
C: -1.71%
breast cancer treatment sabcs
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
Published: 2023-11-08 (Crawled : 21:00) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: -0.09%
H: 0.0%
C: -5.18%
breast cancer treat trial
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
Published: 2023-10-04 (Crawled : 15:00) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 0.68%
H: 0.24%
C: -2.46%
lung cancer publication risk
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Published: 2023-09-14 (Crawled : 15:00) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 0.32%
H: 0.41%
C: -5.51%
breast cancer collaboration
United States Women Health Laboratory Testing Market Analysis 2023-2028 - Cancer Prevalence Among Women Creates New Opportunities
Published: 2023-08-08 (Crawled : 16:00) - prnewswire.com
LH M | $206.2 -0.85% 67K
|
Health Services
|
| O: -0.76%
H: 0.7%
C: 0.52%
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 0.69%
H: 3.99%
C: 2.63%
health cancer women market
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
Published: 2023-07-28 (Crawled : 15:00) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 1.61%
H: 0.92%
C: -0.37%
cancer trial
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 0.12%
H: 1.17%
C: -3.29%
asco cancer meeting
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Published: 2023-05-08 (Crawled : 14:00) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: -0.07%
H: 0.37%
C: -1.78%
breast cancer publication trial
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: -1.54%
H: 1.59%
C: -1.56%
symposium gastrointestinal asco cancer
Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer
Published: 2023-01-17 (Crawled : 14:20) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: -1.05%
H: 1.4%
C: -3.33%
cancer publication study
Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium
Published: 2022-12-07 (Crawled : 15:00) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: -1.21%
H: 1.93%
C: 0.34%
breast symposium cancer
Global Liquid Biopsy Market Report 2022: Increased Awareness Regarding Cancer Boosts 13.77% Annual Growth
Published: 2022-11-08 (Crawled : 21:00) - prnewswire.com
BIO | $281.99 -1.15% 28K
|
Health Technology
|
| O: -0.44%
H: 6.91%
C: 6.14%
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 3.06%
H: 0.43%
C: -15.25%
MYGN | $18.48 -0.65% 16K
|
Health Technology
|
| O: -0.78%
H: 5.43%
C: 3.08%
ILMN | $122.54 -1.54% 84K
|
Health Technology
|
| O: -1.08%
H: 1.4%
C: 0.07%
BIOC | $0.4349 -10.32% 750K
|
Health Services
|
| O: -1.24%
H: 3.8%
C: -6.33%
global report cancer growth market
New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer
Published: 2022-10-06 (Crawled : 13:20) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 0.45%
H: 1.75%
C: 0.38%
test cancer publication ovarian cancer
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
Published: 2022-09-12 (Crawled : 15:20) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 1.25%
H: 0.0%
C: -0.5%
treatment cancer
Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive Bladder Cancer
Published: 2022-07-18 (Crawled : 16:00) - biospace.com/
NTRA | News M | $93.155 2.32% 83K
|
Health Services
|
| O: 0.83%
H: 4.89%
C: -5.67%
test bladder cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
TROO | $1.41 29.36% 280K
|
Manufacturing
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
RCAT | $1.52 26.67% 1.3M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.